Guggenheim Maintains Buy on Johnson & Johnson, Raises Price Target to $287

Benzinga Newsdesk www.benzinga.com Positive 89.7%

Neg 0% Neu 0% Pos 89.7%

Guggenheim analyst Vamil Divan maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $270 to $287.